Tags

Type your tag names separated by a space and hit enter

[Treatment refractory schizophrenia].
Encephale. 1995 Jun; 21 Spec No 3:13-21.E

Abstract

Historically, first case-report of resistant schizophrenia were described under insulin therapy. Later on, the development of classical neuroleptics has permitted a better outcome but the persistence of a lack of improvement in certain patients has induced the individuation of treatment-refractory schizophrenia criteria. The difficulties in defining the refractory schizophrenic patients are described: variability of the schizophrenia diagnostic criteria, variability of outcome, lack of consensus about the good practices in neuroleptic treatment, difficulties in defining response criteria and the confusion between resistance, chronicity and severity. Three kinds of treatment refractory schizophrenia criteria are available: by Kane et al., May et Dencker, Brenner Dencker et al. There are few studies including resistant schizophrenic patients: their results are not homogeneous, perhaps because the prevalence of treatment-refractory schizophrenia is poorly known, with ranges from 5 to 25%. The following factors are hypothesized as being readily associated to a poor outcome and perhaps resistance: male sex, early illness beginning, severity of negative or formal thought disorder, absence of an affective syndrome, morphological CT scans abnormalities, pharmacological factors, late treatment initiation, variability of biodisposibility... Then the therapeutic point of view is considered under three main axes: neuroleptic drugs (NLP) are the basis of chemotherapy, but other therapeutic approaches complete the biological treatment: coherent institutional work and implication of family environment.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

Service Hospitalo-Universitaire de Santé Mentale et de Thérapeutique, Centre hospitalier Sainte-Anne, Paris.

Pub Type(s)

English Abstract
Journal Article
Review

Language

fre

PubMed ID

7628336

Citation

Vanelle, J M.. "[Treatment Refractory Schizophrenia]." L'Encephale, vol. 21 Spec No 3, 1995, pp. 13-21.
Vanelle JM. [Treatment refractory schizophrenia]. Encephale. 1995;21 Spec No 3:13-21.
Vanelle, J. M. (1995). [Treatment refractory schizophrenia]. L'Encephale, 21 Spec No 3, 13-21.
Vanelle JM. [Treatment Refractory Schizophrenia]. Encephale. 1995;21 Spec No 3:13-21. PubMed PMID: 7628336.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Treatment refractory schizophrenia]. A1 - Vanelle,J M, PY - 1995/6/1/pubmed PY - 1995/6/1/medline PY - 1995/6/1/entrez SP - 13 EP - 21 JF - L'Encephale JO - Encephale VL - 21 Spec No 3 N2 - Historically, first case-report of resistant schizophrenia were described under insulin therapy. Later on, the development of classical neuroleptics has permitted a better outcome but the persistence of a lack of improvement in certain patients has induced the individuation of treatment-refractory schizophrenia criteria. The difficulties in defining the refractory schizophrenic patients are described: variability of the schizophrenia diagnostic criteria, variability of outcome, lack of consensus about the good practices in neuroleptic treatment, difficulties in defining response criteria and the confusion between resistance, chronicity and severity. Three kinds of treatment refractory schizophrenia criteria are available: by Kane et al., May et Dencker, Brenner Dencker et al. There are few studies including resistant schizophrenic patients: their results are not homogeneous, perhaps because the prevalence of treatment-refractory schizophrenia is poorly known, with ranges from 5 to 25%. The following factors are hypothesized as being readily associated to a poor outcome and perhaps resistance: male sex, early illness beginning, severity of negative or formal thought disorder, absence of an affective syndrome, morphological CT scans abnormalities, pharmacological factors, late treatment initiation, variability of biodisposibility... Then the therapeutic point of view is considered under three main axes: neuroleptic drugs (NLP) are the basis of chemotherapy, but other therapeutic approaches complete the biological treatment: coherent institutional work and implication of family environment.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0013-7006 UR - https://www.unboundmedicine.com/medline/citation/7628336/[Treatment_refractory_schizophrenia]_ L2 - http://www.diseaseinfosearch.org/result/6442 DB - PRIME DP - Unbound Medicine ER -